BIOTECH
The Biotech Sector: Vibrant and Volatile Excerpted from Vantage 2019 Preview by Amy Brown, Jonathan Gardner and Edwin Elmhirst
33 | HS&M MARCH/APRIL 2019
THE BIG PICTURE While biopharma has been the focus of a lot of attention and activity recently, Vantage’s assessment of 2019 suggests that it’s headed for rough waters. Here’s a sample of the metrics and predictions from their insights. Biopharma is heading into 2019 on very shaky footing. The turmoil has largely been triggered by fears from beyond the sector. It is hard to predict how much further markets might fall, though most agree that a more volatile year is approaching.
